Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ventrus Biosciences Inc. is ready to take its lead candidate iferanserin, a novel compound aimed at arresting hemorrhoid symptoms rather than soothing them, into Phase III studies after the micro-cap biotech's late-December initial public offering brought in $20 million to support the program.